Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
16/09/2026 10:48
BRIEF-WHO Names Resomelagon Among Key Dengue Drug Candidates Sept 16 (Reuters) - SynAct Pharma AB SYNACT.ST:
WHO IDENTIFIES RESOMELAGON AS ONE OF SIX DENGUE DRUG CANDIDATES WITH EVIDENCE SUPPORTING FURTHER CLINICAL DEVELOPMENT
Source text: ID:nMFN1y9p4N
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development